The Mayne Pharma Group Ltd (ASX: MYX) share price has continued to slide lower and in afternoon trade is down 4% to $1.02.
This latest decline brings the pharmaceutical company's year-to-date decline to 25%.
Despite its shares changing hands at 10x annualised earnings, investors continue to stay away amid concerns over price-fixing allegations and Donald Trump's policies of generic drug prices.
Unfortunately for shareholders, it seems as though the only people interested in its shares at present are short sellers.
Earlier this week we revealed that Mayne Pharma is one of the most shorted shares on the Australian share market with short interest of 13.2%.
Lithium miner Orocobre Limited (ASX: ORE) is the most shorted share on the ASX at present. Approximately 20.1% of its shares are in the hands of short sellers according to data provided by ASIC.
